Fairmount Funds Management LLC
Top Portfolio Positions
12 positions ·
$1,457,080,670 total
· as of Mar 31, 2026
| Ticker | Company | Shares | Value (USD) | % of Portfolio | Open |
|---|---|---|---|---|---|
| DMRA |
Damora Therapeutics, Inc.
Healthcare
|
8,713,000 | $225,666,700 | 15.49% | |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
Healthcare
|
2,537,191 | $212,921,068 | 14.61% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
5,503,418 | $211,826,558 | 14.54% | |
| SYRE |
Spyre Therapeutics, Inc.
Healthcare
|
4,018,101 | $202,673,014 | 13.91% | |
| ORKA |
Oruka Therapeutics, Inc.
Healthcare
|
3,705,262 | $181,743,101 | 12.47% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
3,711,288 | $145,482,488 | 9.98% | |
| VRDN |
Viridian Therapeutics, Inc.DE
Healthcare
|
3,914,458 | $76,566,798 | 5.25% | |
| JBIO |
Jade Biosciences, Inc.
Healthcare
|
4,553,494 | $63,976,590 | 4.39% | |
| CBIO |
Crescent Biopharma, Inc.
Healthcare
|
2,747,866 | $50,478,298 | 3.46% | |
| ZBIO |
Zenas BioPharma, Inc.
Healthcare
|
2,359,025 | $46,118,938 | 3.17% |
Portfolio Trend
25 quarters · across all stocks
Holdings in COGT
Shares Held
Position Value (USD)
24 quarters on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $211,826,558 | 5,503,418 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $319,801,407 | 9,003,418 | Shares | Sole | 2026-02-17 | |
| 2025-11-13 | $537,133,050 | 15,877,418 | Shares | Sole | 2025-11-17 | |
| 2025-09-30 | $129,289,082 | 9,003,418 | Shares | Sole | 2025-11-14 | |
| 2025-07-10 | $155,425,360 | 14,324,918 | Shares | Sole | 2025-07-14 | |
| 2025-06-30 | $44,700,102 | 6,225,641 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $37,291,589 | 6,225,641 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $48,559,999 | 6,225,641 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $67,236,922 | 6,225,641 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $52,482,153 | 6,225,641 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $31,756,307 | 4,725,641 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $20,926,773 | 3,558,975 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $34,700,006 | 3,558,975 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $42,138,264 | 3,558,975 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $29,769,340 | 2,758,975 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $31,893,751 | 2,758,975 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $41,163,907 | 2,758,975 | Shares | Sole | 2022-11-09 | |
| 2022-06-30 | $24,885,954 | 2,758,975 | Shares | Sole | 2022-08-15 | |
| 2022-03-31 | $11,676,722 | 1,558,975 | Shares | Sole | 2022-05-16 | |
| 2021-12-31 | $13,376,005 | 1,558,975 | Shares | Sole | 2022-02-14 | |
| 2021-09-30 | $13,110,979 | 1,558,975 | Shares | Sole | 2021-11-15 | |
| 2021-06-30 | $12,643,287 | 1,558,975 | Shares | Sole | 2021-08-13 | |
| 2021-03-31 | $13,687,800 | 1,558,975 | Shares | Sole | 2021-05-14 | |
| 2020-12-31 | $17,507,289 | 1,558,975 | Shares | Sole | 2021-02-12 | |
| No 13F history on record for this holder in this stock. | ||||||